Literature DB >> 7189466

Intranigral GABA antagonists produce dopamine-independent biting in rats.

J Arnt, J Scheel-Krüger.   

Abstract

Behavioural effects following bilateral intranigral administration of GABA antagonists have been investigated. Bicuculline methiodide (BMI), picrotoxin and isopropylbicyclophosphate all induced biting behaviour, teeth-chattering and chewing. Sub-threshold doses for biting induced locomotor activity and sniffing. The strongest response was observed after injection into the caudal pars reticulata, whereas weaker effects were seen after injection into the rostral pars reticulata or the pars compacta. The biting induced by intranigral BMI was not antagonized by prior catecholamine depletion with reserpine plus alpha-methyl-p-tyrosine or by dopamine receptor blockade with haloperido. Concomitant intranigral injection of the GABA agonists muscimol and THIP, however, completely antagonized biting. Systemic GABAergic drugs also antagonized the BMI-induced biting: the benzodiazepine, diazepam and the GABA transaminase inhibitor, gamma-acetylenic GABE, were most effective, whereas muscimol was only partially effective and THIP was without effect. It is suggested that this animal model may be used for the evaluation of antidyskinetic drugs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7189466     DOI: 10.1016/0014-2999(80)90480-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Biochemical and behavioural properties of clozapine.

Authors:  D M Coward; A Imperato; S Urwyler; T G White
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Motor effects following application of putative excitatory amino acid antagonists to the region of the mesencephalic dopamine cell bodies in the rat.

Authors:  D Dawbarn; C J Pycock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-12       Impact factor: 3.000

3.  The effects of muscimol and picrotoxin injections into the cat substantia nigra.

Authors:  S Wolfarth; W Kolasiewicz; K H Sontag
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-08       Impact factor: 3.000

4.  Effect of apomorphine and gabaergic drugs in monkeys pretreated with haloperidol.

Authors:  N Bjørndal; J Gerlach; D E Casey; E Christensson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  Oral behaviour induced by intranigral muscimol is unaffected by haloperidol but abolished by large lesions of superior colliculus.

Authors:  E B Taha; P Dean; P Redgrave
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Intranigral infusion of enkephalins elicits dyskinetic biting in rats.

Authors:  U Liminga; P Johansson; I Nylander; L M Gunne
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Comparison of the CNS effects induced by TRH and bicuculline after microinjection into medial septum, substantia nigra and inferior colliculus: absence of support for a GABA antagonist action for TRH.

Authors:  G R Breese; G D Frye; T J McCown; R A Mueller
Journal:  Pharmacol Biochem Behav       Date:  1984-07       Impact factor: 3.533

8.  Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities.

Authors:  S Mithani; S Atmadja; K G Baimbridge; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  Non-dopaminergic neurones of the reticular part of substantia nigra can gate static fusimotor action onto flexors in cat.

Authors:  M Schwarz; K H Sontag; P Wand
Journal:  J Physiol       Date:  1984-09       Impact factor: 5.182

10.  Pars compacta of the substantia nigra modulates motor activity but is not involved importantly in regulating food and water intake.

Authors:  G K Hodge; L L Butcher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.